Bergen, Norway 21 April 2022
Today, Lifecare 2021 annual report is published. 2021 was marked by severalimportant milestones:
o Regulatory approval for first-in-human pilot clinical trials o Restructuring the organization - controlling development operationso Reinforced Patent Protection and IPo Successful Capital Increase
The report is subject to approval by the company's general meeting on 6 May2022.
Lifecare AS' management team will host an online presentation of the 2021 annualresults today at 13:00 - 14:00 CET. The presentation will also includedevelopment outlook and assumptions related to the patient and market potentialfor Sencell. The report and the presentation are attached to this release andare also available on Lifecare's website. The basis for the Sencell marketpotential can be downloaded athttps://lifecare.no/publications/sencell-market-assumptions-and-commercial-potential-april-2022/ There will be a Q&A session following the managementpresentation.
The link to the webcast is available in the Investors section:https://lifecare.no/events/webcast-annual-report-2021/. You can post questionsduring the event or send them in advance to: kine.hereid@lifecare.attme.dev
Further informationJoacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.attme.dev, +47 40 05 90 40
This information is subject to the disclosure requirements pursuant to Section5-12 the Norwegian Securities Trading Act. This stock exchange announcement waspublished by Kine Hereid, Investor Relations at Lifecare AS, on 21 April 2022 at11:00 CET.